Selected Publications

Porter DL, Levine BL, Kalos M, Bagg A, June CH: Delayed tumor lysis and CLL remission from chimeric antigen receptor modified T cells New England Journal of Medicine 365 : 725-733,2011.

Reshef R, Luger S, Hexner EO, Loren AW, Frey NV, Nasta SD, Goldstein SC, Stadmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie JA, Vonderheide RH, Porter DL.: Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease New England Journal of Medicine 367 : 135-145,2012.

Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH.: T cells expressing chimeric receptors establish memory and potent antitumor effects in patients with advanced leukemia Science Translational Medicine 3 : 95ra73,2011.

Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL.: Peripheral blood stem cells versus bone marrow from unrelated donors: results of Blood and Marrow Transplant Clinical Trials Network protocol 0201, a phase III, prospective, randomized trial. New England Journal of Medicine 367 : 1487-1496,2012.

Porter DL, Alyea EP, Antin JH, DeLima M, Estey, E, Falkenburg JHF, Hardy N, Kroeger N, Leis J, Levine J, Maloney DG, Peggs K, Rowe JM, Wayne AS, Giralt S, Bishop MR, van Besien K.: NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood and Marrow Transplant 16 : 1467-1503,2010.

Tizon R, Frey N, Heitjan DF, Tan KS, Goldstein SC, Hexner EO, Loren A, Luger SM, Reshef R, Tsai D, Vogl D, Davis J, Vozniak M, Fuchs B, Stadtmauer EA, Porter DL.: High dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allogeneic SCT. Bone Marrow Transplant 47 : 1332-1337 ,2011.

Rager A, Frey N, Goldstein SC, Reshef R, Hexner EO, Loren A, Luger SM, Perl, A, Tsai D, Davis J, Vozniak M, Smith J, Stadtmauer EA, Porter DL.: Inflammatory Cytokine Inhibition with Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease Bone Marrow Transplantation epub : 2010.

Paralkar VR, Nasta SD, Morrissey K, Smith J, Vassilev P, Martin ME, Goldstein SC, Loren A, Rook AH, Kim EJ, Porter DL.: Allogeneic hematopoietic stem cell transplantation for primary cutaneous T cell lymphomas Bone Marrow Transplantation 47 : 940-945,2012.

Rager A, Porter DL: Cellular therapy following allogeneic stem cell transplantation Therapeutic Advances in Hematology 2 (6): 416 - 435.,2011.

Goldstein SC, Porter DL: Allogeneic immunotherapy to optimize the graft-versus tumor effect: concepts and controversies. Expert Review of Hematology 3 (3): 301-314,2010.

Porter DL, Hexner EO, Cooley S, Miller JS: Cellular adoptive immunotherapy after autologous and allogeneic hematopoietic stem cell transplantation Hematopoietic Stem Cell Transplantation : 2008.

Goldstein S, Stein S, Porter DL: Treatment of Acute Graft vs Host Disease Allogeneic Stem Cell Transplantation. Clinical Research and Practice 2 : 747-765,2010.

Loren AW, Porter DL: Donor Leukocyte Infusions for the Treatment of Relapsed Acute Leukemia After Allogeneic Stem Cell Transplantation Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplantation 41 : 483,2007.

Porter, DL: RIC for MDS: The Glass is Half Full (commentary). , Blood 108 : 780-781,2006.

Porter DL, Antin JH: Donor Leukocyte Infusions in Myeloid Malignancies: New Strategies. Best Practice and Research: Clinical Hematology 19 (4): 737-756,2006.

Porter DL, Stadtmauer EA, Lazarus H.: "GVHD": Graft-vs-Host Disease or Graft-vs-Hodgkin's Disease? An Old Acronym with New Meaning. Bone Marrow Transplant 31 : 739-746,2003.

Loren AW, Luger SM, Duffy KM, Stadtmauer E, Tsai D, Schuster S, Nasta S, Klumpp T, Orloff G, Porter D.: Alemtuzumab prevents acute graft-vs-host disease (aGVHD) in non-myeloablative stem cell transplants (NST) from unrelated donors. Proc Am Soc Clin Oncol : 2003.

Academic Contact Information

Hematology-Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-150
3400 Civic Center Blvd
Philadelphia, PA 19104
Phone: 215-662-2867
Patient appointments: 800-789-7366